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Gamma Knife surgery (GKS) is a noninvasive pro-cedure, increasingly used in many intracranial conditions, including trigeminal neuralgia (TN). Leksell, the inventor of GKS, performed the first radio-surgical treatment in 1951.35,36 In 1981, Håkanson discov-ered that the glycerol injection, made for GKS targeting 
purposes, could also be used as a therapy in TN.20,21 In 
1985, once MR imaging was available for clinical use on 
a large scale, modern dose planning was implemented.37 
In 1993, Rand et al.45,46 advocated that the ganglion was 
not a good target and proposed to shift the target to the 
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Object. The purpose of this study was to establish the safety and efficacy of repeat Gamma Knife surgery (GKS) 
for recurrent trigeminal neuralgia (TN).
Methods. Using the prospective database of TN patients treated with GKS in Timone University Hospital (Mar-
seille, France), data were analyzed for 737 patients undergoing GKS for TN Type 1 from July 1992 to November 
2010. Among the 497 patients with initial pain cessation, 34.4% (157/456 with ≥ 1-year follow-up) experienced at 
least 1 recurrence. Thirteen patients (1.8%) were considered for a second GKS, proposed only if the patients had 
good and prolonged initial pain cessation after the first GKS, with no other treatment alternative at the moment of 
recurrence. As for the first GKS, a single 4-mm isocenter was positioned in the cisternal portion of the trigeminal 
nerve at a median distance of 7.6 mm (range 4–14 mm) anterior to the emergence of the nerve (retrogasserian target). 
A median maximum dose of 90 Gy (range 70–90 Gy) was delivered. Data for 9 patients with at least 1-year follow-
up were analyzed. A systematic review of literature was also performed, and results are compared with those of the 
Marseille study.
Results. The median time to retreatment in the Marseille study was 72 months (range 12–125 months) and in 
the literature it was 17 months (range 3–146 months). In the Marseille study, the median follow-up period was 33.9 
months (range 12–96 months), and 8 of 9 patients (88.9%) had initial pain cessation with a median of 6.5 days (range 
1–180 days). The actuarial rate for new hypesthesia was 33.3% at 6 months and 50% at 1 year, which remained stable 
for 7 years. The actuarial probabilities of maintaining pain relief without medication at 6 months and 1 year were 
100% and 75%, respectively, and remained stable for 7 years. The systematic review analyzed 20 peer-reviewed stud-
ies reporting outcomes for repeat GKS for recurrent TN, with a total of 626 patients. Both the selection of the cases 
for retreatment and the way of reporting outcomes vary widely among studies, with a median rate for initial pain 
cessation of 88% (range 60%–100%) and for new hypesthesia of 33% (range 11%–80%).
Conclusions. Results from the Marseille study raise the question of surgical alternatives after failed GKS for TN. 
The rates of initial pain cessation and recurrence seem comparable to, or even better than, those of the first GKS, ac-
cording to different studies, but toxicity is much higher, both in the Marseille study and in the published data. Neither 
the Marseille study data nor literature data answer the 3 cardinal questions regarding repeat radiosurgery in recurrent 
TN: which patients to retreat, which target is optimal, and which dose to use.
(http://thejns.org/doi/abs/10.3171/2014.8.GKS141487)
Key WoRDs      •      Gamma Knife surgery      •      trigeminal neuralgia      •      retreatment      •       
stereotactic radiosurgery
Abbreviations used in this paper: BNI = Barrow Neurological 
Institute; DREZ = dorsal root entry zone; GKS = Gamma Knife 
surgery; MVD = microvascular decompression; TN = trigeminal 
neuralgia.
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cisternal part. 50 In 1996, Kondziolka et al.34 published a 
multicenter study that established the minimal therapeu-
tic dose necessary to be effective.50 In 1994, Lindquist 
coined the term “dorsal root entry zone (DREZ) target” 
(corresponding in fact to the anatomical emergence of the 
trigeminal nerve).37 In 2000, Pollock et al.43 published the 
first paper on repeat radiosurgery for TN, and in 2006 Ré-
gis et al.49 published the only prospective controlled trial 
using GKS as a therapy for medically unresponsive TN.
Since 1996, the number of available papers advocat-
ing the safety and efficacy of GKS in idiopathic TN has 
grown continuously; however, studies describing repeat ra-
diosurgery are scarce. Furthermore, there are no clear-cut 
guidelines for indication or technique for repeat radiosur-
gery, such as patient selection criteria for retreatment, dose, 
location of the isocenter, or whether to plug the collimator 
apertures. Therefore, we present our own study of patients 
treated in Timone University Hospital, Marseille, France, 
and compare our results with systematically reviewed pub-
lished data on repeat radiosurgery for recurrent TN.
Methods
Marseille Study
This was designed as an open, self-controlled, non-
comparative, retrospective study. For all patients, a case 
report form was created and filled in prospectively. All 
patients were examined before treatment, and MR imag-
ing was performed (the latest images were used to ex-
clude any secondary cases). Permission was obtained 
from the Timone University Hospital ethics committee 
for this study.
Patients. Between July 1992 and November 2010, pa-
tients presenting with intractable TN were prospectively 
selected and treated with radiosurgery in Timone Univer-
sity Hospital, Marseille, France. We included in our study 
patients undergoing repeat GKS for recurrent TN with 
more than 1 year of follow-up.
Cases of TN secondary to multiple sclerosis58 or due 
to megadolichobasilar artery compression60 were exclud-
ed from our analysis, as they are reputed to have different 
clinical outcomes.
All patients were treated by the senior neurosurgeon 
(J.R.).
Diagnostic Criteria Using the International Head-
ache Society Definition. All patients fulfilled the TN cri-
teria of the International Headache Society.23 Evaluation 
of the type of trigeminal pain was made according to the 
classification proposed by Eller et al.15: idiopathic TN 
Type 1, described as typically sharp, shooting, electrical 
shock–like, with pain-free intervals between the attacks, 
present for more than 50% of the time; and TN Type 2, 
described as an aching, throbbing, or burning pain, pres-
ent for more than 50% of the time and constant in na-
ture (constant background pain being the most significant 
attribute). Only patients fulfilling the criteria of the TN 
Type 1 were included in the present study.
Patient Selection Criteria for Retreatment and Tech-
nique. Retreatment was proposed only if patients had good 
and prolonged pain cessation after initial GKS, with no 
other surgical alternative at the moment of recurrence. We 
used the same target and same ranges of doses as for the 
first GKS. All patients underwent repeat GKS. After ap-
plication of the Leksell Model G stereotactic frame (Elekta 
AB) under local anesthesia, patients underwent stereotac-
tic MR imaging and CT imaging for target definition. The 
MR image sequences used to identify the trigeminal nerve 
were T2-type CISS (constructive interference in steady 
state) (Siemens S.A.S.) without contrast, and contrast-en-
hanced T1-weighted images. Bone CT imaging routinely 
supplements the neuroradiological investigation to correct 
any distortion errors on the MR image.49,59
Between July 1992 and November 2010, the Gamma 
Knife (model B, C, or 4C; Elekta AB) was successively 
used. A single 4-mm isocenter was used in all patients, 
for both the first and the second GKS, positioned in the 
anterior cisternal portion of the trigeminal nerve at a me-
dian distance of 7.6 mm (range 4–14 mm) anterior to the 
emergence of the nerve (retrogasserian target). This target 
has been used in our center since the beginning of GKS 
treatments for TN, as detailed in previous studies47–50 
(Fig. 1).
The median maximum dose delivered during the 
first treatment was 85 Gy (range 70–90 Gy) and at re-
treatment it was 90 Gy (range 70–90 Gy). The dose was 
chosen according to the multicenter trial of Kondziolka 
et al.34 (which included an substantial number of patients 
from our center), which recommended a minimal dose of 
70 Gy for short- and/or long-term efficacy, a cutoff our 
group was using before the publication of that trial. Fur-
thermore, we initially give a dose of 90 Gy at the 100% 
isodose. Beam channel blocking is used based on the 
dose received by 10 mm3 of the brainstem: if this dose is 
greater than 15 Gy, we diminish the dose and then start 
plugging the collimator apertures to avoid increasing the 
length of the treated nerve, which could account for more 
toxicity (the so-called Flickinger effect).16
Follow-Up Monitoring. Patients and referring physi-
cians were instructed to follow the pretreatment medica-
tion regimen for at least 1 month after GKS and then to 
diminish the doses progressively in periods of pain free-
dom.
Initial follow-up was based on clinical evaluation at 
regular intervals of 3 months, 6 months, and 1 year after 
the treatment and on a yearly basis thereafter. We have 
personally examined all patients for proper evaluation 
of safety and efficacy, including facial sensory testing, 
corneal reflex, and jaw motility. For long-term follow-up, 
telephone interview was considered acceptable for pa-
tients unable to visit the clinic because of either distance 
or general health-related conditions.
Every clinical evaluation made by our medical team 
during follow-up was prospectively noted in the database. 
The 15 items of data considered essential by Zakrzewska 
and Thomas66 for articles reporting outcomes of surgical 
treatment of TN were followed.
Explicit Definitions of Outcome Measures. Outcome 
measures included initial pain cessation and onset and re-
currence of the sensory disturbance. Efficacy was classi-
C. Tuleasca et al.
212                                                                                                                      J Neurosurg / Volume 121 / December 2014
fied according to the Barrow Neurological Institute (BNI) 
scale: Class I, no trigeminal pain, no medication; Class II, 
occasional pain, not requiring medication; Class IIIa, no 
pain with continued medication; Class IIIb, pain controlled 
with medication; Class IV, some pain, not adequately con-
trolled with medication; and Class V, severe pain, no pain 
relief. A successfully treated patient was considered a pa-
tient who was pain free without medication (BNI Class I).
The degree of hypesthesia is reported using the BNI 
facial hypesthesia scale: Class I, no facial numbness; 
Class II, mild facial numbness, not bothersome; Class III, 
facial numbness, somewhat bothersome; and Class IV, 
facial numbness, very bothersome.51 The corneal reflex 
was assessed for all patients. Additionally, the occurrence 
or absence of dysesthesias, paresthesias, anesthesia do-
lorosa, masseter weakness, neurological complications 
outside the trigeminal nerve territory, systemic complica-
tions, and death were noted.
Recurrence was defined as change from Class I to a 
lower outcome class during follow-up. Thus, recurrence 
was considered to have happened in a patient who had 
been pain free without medication (Class I) and who then 
started taking specific drugs again but who remained 
pain free on medication (Class II).
A minor recurrence was defined as one that was well 
tolerated by the patient (lower frequency and intensity 
of the pain) and did not require additional treatment. A 
major recurrence was defined as one requiring a surgi-
cal procedure. We use the term “initial efficacy” when a 
patient is pain free with or without medication in the first 
6 months after the radiosurgery and has no recurrence in 
the year that follows the procedure.
The latency intervals to becoming pain free or de-
veloping a recurrence or a sensory disturbance, the date 
of medication changes, and the date of all surgical proce-
dures were also monitored. Patient satisfaction was evalu-
ated at the last follow-up.
Statistical Analysis. All statistical analyses were per-
formed using R software (version 2.12.0, R Foundation 
for Statistical Computing). The R package “survival” was 
used for survival analysis. For the evaluation of outcomes 
such as pain free, hypesthesia, and recurrence, time to 
event was estimated using the Kaplan-Meier method. A 
bivariate analysis was then performed to identify predic-
tive factors among the collected variables. Qualitative 
variables were compared using the univariate log-rank 
test, with survival among the different groups represented 
graphically with Kaplan-Meier curves. For all variables, 
the effects were estimated and tested by fitting univariate 
Cox proportional hazards regression models. Proportion-
ality of hazards was assessed graphically by log cumu-
lative hazard plots. For qualitative variables, chi-square 
tests were performed when valid; otherwise, exact Fisher 
tests were used. For quantitative variables, Mann-Whit-
ney tests were performed given the number of patients. 
All tests were 2-sided, and p values < 0.05 were deemed 
significant.
Systematic Review
Search Strategy and Selection Criteria. The PubMed 
database was queried using the following word combina-
tions in the “title” item: (“repeat” AND “radiosurgery” 
AND “trigeminal”), (“recurrent” AND “radiosurgery” 
AND “trigeminal”), and (“salvage” AND “radiosurgery” 
AND “trigeminal”). The bibliographies of the identified 
studies were also searched to ensure that no qualifying 
references were missed. Additionally, we used the Google 
search engine to expand our list of studies, including ab-
stracts, but we considered in the final analysis only peer-
reviewed papers. We did not restrict returns by year of 
publication; all published studies were eligible for selec-
tion if they fulfilled the criteria. There were no language 
restrictions.
Suitable studies were peer reviewed and contained 
data on patients who underwent repeat radiosurgery for 
recurrent TN, and reported rates of initial pain cessation, 
hypesthesia, and recurrence. Papers reporting retreatment 
as a subgroup were included if they had a minimum num-
ber of 13 cases, as this was the number of our study. We 
excluded studies that did not meet these criteria.
Three investigators (C.T., M.L., and J.R.) extracted 
data independently and in duplicate and assessed trial 
eligibility and quality. Disagreements were resolved by 
consensus.
Fig. 1. The retrogasserian target used in our institution (Timone Uni-
versity Hospital, Marseille, France).
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Outcomes. We extracted the primary outcomes, ini-
tial pain cessation, hypesthesia, and recurrence, and their 
positive and negative predictive factors. Secondary data 
extracted were selection criteria and patient profile for 
retreatment, the number of retreatments versus the total 
number of patients in the same institution/trial, mean/
median interval between first and second radiosurgical 
treatments, placement of the target and the doses used 
for first and second treatments, complications other than 
hypesthesia, and criteria used to report the outcomes.
Results
Marseille Study
Between July 1992 and November 2010, 737 patients 
were treated for TN at Timone University Hospital (Mar-
seille, France). Among the 497 patients in our study with 
initial pain cessation after the first GKS, 34.4% (157 of 
456 patients with ≥ 1-year follow-up) experienced at least 
1 recurrence. Thirteen of the 737 patients (1.8%) had re-
peat GKS for recurrent TN; 9 patients with more than 1 
year of follow-up were further analyzed. The median fol-
low-up period for these 9 patients was 33.9 months (range 
12–96 months). The median age at second GKS was 64.4 
years (range 53.7–83.1 years). All the patients presented 
with typical TN Type 1 pain.
Details of Previous Treatments. Previous treatments 
are detailed in Table 1. All patients (100%) had prior sur-
gical procedures, of whom 4 (44.4%) had only 1 previous 
intervention, 2 (22.2%) had 2 previous surgeries, and 3 
(33.4%) had 3 or more previous surgeries. Previous sur-
geries consisted of radiofrequency lesioning in 4 patients 
(44.4%), balloon microcompression in 1 (11.1%), and mi-
crovascular decompression (MVD) in 1 (11.1%). Before 
GKS, 3 patients (33.3%) had sensory disturbance related 
to a previous surgical procedure, consisting of slight hyp-
esthesia in 2 (22.2%) and severe hypesthesia in 1 (11.1%).
Initial Rate of Pain Cessation. Eight of 9 patients 
(88.9%) were initially pain free in a median time of 6.5 
days (range 1–180 days) after retreatment and 10 days 
(range 1–180 days) after first GKS. The initially pain ces-
sation actuarial rate at 0.5, 1, 2, 3, 4, 5, and 6 months was, 
respectively, 53.52%, 73%, 83.5%, 88.1%, 88.9%, 89.5%, 
and 91.3% after the first GKS (Fig. 2) and 33.3%, 44.4%, 
44.4%, 55.6%, 55.6%, 66.7%, and 88.9% after retreat-
ment. No statistically significant predictors were found 
for being initially pain free after the second GKS, but the 
small number of patients limits statistical power.
Postoperative Sensory Assessment. No patients sus-
tained early complication after the second GKS. Three 
patients (33.3%) developed later objective facial sensory 
loss, which occurred during the 1st year after retreatment 
and was mild in all cases. The hypesthesia actuarial rate 
was 33.3% at 6 months; at 1 year it reached 50% and re-
mained stable for 7 years (Fig. 3). For all patients with 
idiopathic TN treated in our institution, we have reported 
a hypesthesia actuarial rate of 21% after first GKS;48 in 
our study of patients undergoing repeat radiosurgery, 
we found a statistically significant higher risk of facial 
numbness (p = 0.0193; hazard ratio 3.97). We also as-
sessed hypesthesia according to the BNI facial hypesthe-
sia scale; mild facial numbness occurred in all 3 patients. 
No patient developed a trigeminal motor deficit or other 
cranial nerve deficit, or anesthesia dolorosa or dry eye 
syndrome after GKS. When asked about their quality of 
life, all patients considered the presence of hypesthesia 
to be a good tradeoff for the disappearance of pain. No 
statistically significant predictors were found for compli-
cations after the second GKS, but the small number of 
patients limits statistical power.
TABLE 1: Pretreatment assessment in the Marseille study (n = 9)
Variable No. of Patients (%)
side of pain
 right 6 (66.7)
 left 3 (33.3)
no. of prior treatments 9 (100)
 1 4 (44.4)
 2 2 (22.2)
 ≥3 3 (33.4)
type of prior treatment
 GKS 9 (100)
 radiofrequency lesioning 4 (44.4)
 balloon microcompression 1 (11.1)
 MVD 1 (11.1)
side effects from prior surgery 3 (33.3)
facial sensation before GKS
 normal 6 (60.5)
 slight hypesthesia 2 (22.2)
 severe hypesthesia 1 (11.1)
Fig. 2. Kaplan-Meier curve showing the actuarial pain cessation 
rates in our series after second GKS (9 patients with ≥ 1-year follow-up).
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Management and Results of Recurrent Pain. Two 
patients (22.2%) who were initially pain free after GKS 
experienced a recurrence. The actuarial probability of 
maintaining pain relief without medication at 6 months 
was 100% and at 1 year reached 75% and remained stable 
for 7 years (Fig. 4). Patients with pain on the left side (p 
= 0.04) and in the V2 dermatome (p = 0.04) had a higher 
risk of recurrence. No other statistically significant pre-
dictors were found, but the small number of patients lim-
its statistical power. 
Two patients (22.2%) needed an additional treatment 
after GKS, with 1 surgery in 1 case (11.1%) and 3 or more 
surgeries in 1 case (11.1%). The further surgical procedures 
performed were balloon microcompression in 2 cases 
(22.2%) and MVD in 1 case (11.1%) (Table 2). All patients 
(100%) expressed a high level of satisfaction, did not regret 
undergoing GKS, and would undergo GKS again.
Systematic Review
Reports Included. The combination of words “repeat 
AND radiosurgery AND trigeminal” in PubMed data-
base gave a number of 25 papers, from which 10 were 
selected,5,14,17,22,24,29,32,40,42,67 including 1 case report;29 using 
“recurrent AND radiosurgery AND trigeminal” returned 
48 studies, from which 7 were selected;1,25–27,43,54,63 and us-
ing “salvage” AND “radiosurgery” AND “trigeminal” 
returned 1 study38 that did not report the outcomes of in-
terest, only the range of doses used at retreatment, so we 
excluded it. After a detailed research of references in the 
included studies and after analyzing all trials published 
on idiopathic TN treated with GKS, 3 further studies 
were included, giving a total of 20 studies (Tables 3–5).
Interestingly, no dedicated study was found when 
searching for retreatment using linear accelerators, only 
sparse information without outcomes.13,57
Study Analysis. The final analysis included 20 peer-
reviewed papers treating the subject of repeat GKS for 
TN, for a total of 626 patients. Only 4 studies contained 
more than 40 patients. All reports were retrospective and 
only 4 had long-term follow-up.17,32,40,62 Although this is a 
large number of patients, analysis was difficult because of 
study heterogeneity. First, the populations of patients were 
heterogeneous at baseline, in terms of previous surgeries 
(highly variable numbers and types) and inclusion of atypi-
cal cases and multiple sclerosis,1,32,63 which are reputed to 
have a different initial pain cessation outcomes.58 Second, 
there was no uniformity of patient selection criteria for re-
treatment. Third, outcomes were assessed differently; qual-
ity of life issues were reported sporadically24 and, if so, on 
Fig. 3. Kaplan-Meier curve showing the actuarial hypesthesia rates 
for first GKS (solid line) and second GKS (dashed line).
Fig. 4. Kaplan-Meier curve showing the actuarial rate for maintain-
ing pain-relief rates after second GKS in the Marseille study.
TABLE 2: Assessment after second GKS in the Marseille study
Variable No. of Patients (%)
initially pain free 8 (88.9)
post-GKS sensory dysfunction 3 (33.3)
 mild 3 (33.3)
 severe 0 (0)
BNI facial hypesthesia scale (GKS related)
 I (no facial numbness) 6 (66.7)
 II (mild facial numbness) 3 (33.3)
 III (facial numbness, somewhat bothersome) 0 (0)
 IV (facial numbness, very bothersome) 0 (0)
recurrence of pain 2 (22.2)
no. of additional treatments after 2nd GKS 2 (22.2)
 1 1 (11.1)
 2 0 (0)
 ≥3 1 (11.1)
balloon microcompression 2 (22.2)
MVD 1 (11.1)
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different scales. Last but not least, the techniques employed 
were also highly variable: target placement and dose pre-
scription play a crucial role in outcomes and should not be 
neglected in this type of analysis.
Outcomes were highly variable, with a median rate 
of initial pain cessation of 88% (range 60%–100%) after 
second GKS and a median hypesthesia rate of 33% (range 
11%–80%).1,5,14,17,22,24–27,29,32,40,42,43,53,54,61–63,67
Patient Profiles. Patients may have different response 
profiles to a first stereotactic radiosurgery, and they are 
heterogeneously represented in the literature: recurrent 
pain after complete response,14,22,40,61 reasonable pain 
control but significant medication-related side effects or 
partial response,17,43,54 or no response at all.5,24 Recurrent 
pain after complete response is a widely accepted indica-
tion for repeat radiosurgery; interventions for the others 
depend on the center’s policy. At Timone University Hos-
pital, the patient criterion for retreatment was initial pain 
cessation without medication, lasting for at least 1 year.
In the published studies, the median time between 
first and second radiosurgery was 17 months (range 3–146 
months); in the Marseille study it was 72 months (range 
12–125 months; Table 3).
Technical Nuances. Technical nuances play a major 
role in surgical outcomes, especially regarding 2 aspects: 
target placement and cumulative dose. Secondary issues 
not specifically related to retreatment are placing 1 versus 
2 isocenters, plugging (which increases the length of the 
treated nerve, the so-called Flickinger effect), and how 
the nerve recovers after a first GKS.
Target Placement. With some exceptions,40,63 most 
of the studies reported using the DREZ as a retreatment 
target, with more than 50% using the identical location 
the first and second time (Table 4). Some reports, such 
as that by Zhang et al.,67 suggested that a longer mean 
distance between isocenters (2.86 vs 1.93 mm) was as-
sociated with better outcomes.
Cumulative Dose. In the studies cumulative dose was 
reported to range between 40 and 90 Gy at retreatment 
(Table 4). Cumulative dose as both a value and a cutoff 
for safety and efficacy remains to be defined. Its real val-
ue is not just adding the first and the second dose. Zhang 
et al.67 stated that if the dose at first GKS is 75 Gy and the 
dose at the second GKS is 40 Gy, with zero as the dis-
tance between isocenters, the cumulative dose would be 
102 and not 115 Gy (however, biological equivalent dose 
has not been taken into account in this evaluation). For 
the same doses, but with a distance of 3 mm between the 
shots, Hasegawa et al.22 found that the cumulative dose 
drops to 95 Gy.
Regarding efficacy, Pollock et al.42 discussed the is-
sue of a cumulative dose of 163.1 Gy versus lower doses 




Follow-Up Period in Mos 
(range) Age in Yrs (range)
Mean Interval Btwn 
1st & 2nd GKS (mos)
present study 13/737 Marseille (France) median 33.9 (15.9–96) median 64.4 (53.7–83.1) median 72 (12–125)
Park et al., 2012 119/503† Pittsburgh, PA (US) median 48 (6–187) median 74 (34–96) median 26 (4–146)
Aubuchon et al., 2011 37 Florida (US) mean 45.6 (7.2–86.4) NA mean 15.6
Jones et al., 2011 1 Seattle, WA (US) 24 72 11
Kimball et al., 2010 45/379 Memphis, TN (US) mean 42 (1–122) mean 68 (30–87) mean 33 (3–138)
Verheul et al., 2010 79/365 Tilburg (the Netherlands) median 28 (3–85) NA NA
Dvorak et al., 2009 28 Boston, MA (US) median 19.7 (1.7–48.9) median 63 median 18.1 (9–55.4)
Gellner et al., 2008 22/93 Graz (Austria) mean 64.5 (13–142) mean 73.5 mean 18.8 (6–63)
Huang et al., 2008 20/89 Taiwan (China) mean 60 (32–87) mean 61.8 (34–83) mean 8 (4.67)
Wang et al., 2008 34/322 X’ian (China) mean 21.6 (7–41) median 68 (42–87) at 1st GKS mean 17.4 (8–34)
Huang et al., 2006 28/118 Taiwan (China) median 43 median 63 (34–77) median 8 (3–67)
Pollock et al., 2005 19 Rochester, MN (US) median 24 (5–67) median 68 (43–83) median 16 (4–55)
Sheehan et al., 2005 14/151 Charlottesville, VA (US) median 19 (after first) median 68 NA
Urgosik et al., 2005 19/107 Prague (Czech Republic) median 36 (12–72) median 75 (45–91) median 12.5 (3–60)
Zhang et al., 2005 40 New York (US) mean 28 (6–51) median 73 (40–90) mean 17 (5–48)
Herman et al., 2004 18/112 Baltimore, MD (US) median 24.5 (6–65) median 62 (31–89) median 8 (3–42)
Brisman, 2003 45/335 Columbia, SC (US) mean 15 mean 70 mean 18 (42–68)
Hasegawa et al., 2002 27/387 Pittsburgh, PA (US) median 20.4 mean 68.7 mean 22.3 (6–73)
Shetter et al., 2002 19/240 Phoenix, AZ (US) median 13.5 NA NA
Zheng et al., 2001 12/80 Tianjin (China) mean 18 mean 67 (32–92) NA
Pollock et al., 2000 10/100 Rochester, MN (US) median 15 median 68 (48–83) median 13 (4–27)
* NA = not applicable.
† The original study published in 2010 by Kondziolka et al. had 503 patients. The paper on retreatments (Park et al., 2012) does not state how many 
total patients they treated to that date.
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(148.5 Gy in the Pittsburgh group,22 143.4 Gy in the Bal-
timore group,24 and 135.7 Gy in the Phoenix group54) and 
stated that there was higher initial pain cessation at high-
er doses, as much as 75% compared with a range between 
19% and 53% for the lower doses.
Dvorak et al.14 proposed the concept of tailoring the 
dose to an individual patient. For debilitating pain they 
propose cumulative doses of more than 130 Gy and po-
tentially more than 150 Gy and accepting a higher rate of 
side effects; for patients with reasonable pain control but 
medication side effects, doses less than 130 Gy seemed 
more appropriate, with a lower rate of side effects. Dvorak 
et al. mainly analyzed 7 peer-reviewed papers, account-
ing for 215 patients, and found an association between 
cumulative dose and pain control (p = 0.04) but also new 
dysfunction (p = 0.08); furthermore, the association be-
tween pain control and new dysfunction was strong (p = 
0.02). They concluded that a dose of 130 Gy or more was 
more successful in terms of pain control but increased 
dysfunction.
Little et al.38 stated that it “seems not to be necessary 
to decrease the doses in patients with prior trigeminal 
dysfunction” and also that there is more Level III evi-
dence for ranges of doses between 40 and 70 Gy. Hasega-
wa et al.22 compared combined high doses (140–160 Gy) 
versus lower doses (120–135 Gy) and concluded that 
there was no difference in recurrence rates but that there 
was increased hypesthesia with the higher doses (32% 
vs 4%). They advocated limiting the cumulative dose to 
140 Gy. Herman et al.24 discussed a cumulative dose of 
145 Gy (75 Gy at first GKS and 70 Gy at second GKS), 
with decreased efficacy but also a low incidence of facial 
numbness. Hasegawa et al.22 suggested that “the best dose 
would eliminate facial pain completely and preserve fa-
cial sensation.” To date, there is no established cut-off for 
dose, and there was a tendency to decrease the dose at 
second GKS in most studies to avoid dysfunction.
Outcomes. Outcomes are summarized in Table 5 and 
are detailed below.
Initial Pain Cessation. With repeat radiosurgery, for 
greater than 50% relief of initial pain the median was 88% 
(range 60%–100%); for complete relief, the median was 
58% (range 18.5%–90%). After initial radiosurgery the 
ranges were 78%–94% and 32%–81%, respectively. After 
both first and second GKS, most patients became pain free 
during the first 6 months; the pain cessation rates were fair-
ly consistent with observations after the first GKS.
TABLE 4: Systematic review of the literature: details of GKS among patients undergoing second GKS*
Authors & Year Initial Dose in Gy (range) 2nd Dose in Gy (range)
Cumulative Dose in Gy 
(range)† Initial Target 2nd Target
present study median 85 (70–90) median 90 (70–90) range 140–180 retrogasserian identical
Park et al., 2012 median 80 (60–90) median 70 (50–90) median 145 (120–170) 3–4 mm 50% overlap
Aubuchon et al., 2011 mean 87.3 (80–90) mean 84.4 (60–90) mean 171.7 (140–180) 50% BS/plex  
 triangularis
distally, unless 1st  
 target distally
Jones et al., 2011 84 54 178 50% BS identical
Kimball et al., 2010 80 70 150 REZ (50%) 4–5 mm distally
Verheul et al., 2010 80 80 160 REZ 50% overlap
Dvorak et al., 2009 median 80 (80–85) median 45 (40–50) median 125 (120–130) 20% BS 2-mm difference
Gellner et al., 2008 mean 75.2 (65–85) mean 74.3 (65–75) 149.5 (130–160) REZ (20% BS) REZ (20% BS)
Huang et al., 2008 mean 79 (60–90) mean 52 (40–76) mean 131 (100–166) REZ (20–30%) identical
Wang et al., 2008 mean 73.4 (60–80) range 60–75 range 120–155 3–4 mm REZ identical
Huang et al., 2006 mean 79.3 (70–90) mean 52 (40–76) mean 131.3 (110–166) REZ (20% BS) identical
Pollock et al., 2005 median 81.6 (76.1–97.9) median 76.1 (65.3–97.9) median 163.1 (152.2–174.0) 20% or lower w/ 
 the BS
anterior
Sheehan et al., 2005 median 80 ≤70 150 NA NA
Urgosik et al., 2005 range 70–80 range 70–80 range 140–160 (mainly  
 same dose)
20% BS 2–4 mm distal
Zhang et al., 2005 75 40 115 40% BS identical
Herman et al., 2004 median 75 (70–80) median 70 (65–75) median 145 (140–155) REZ (20%) identical
Brisman, 2003 median 75 median 40 115 BS 40–50% NA
Hasegawa et al., 2002 mean 75.6 (50–80) mean 64.4 (50–80) 139.4 (125–155) 20% touched  
 the BS
anterior to 1st w/ only  
 50% overlap
Shetter et al., 2002 mean 78.2 (35–80) mean 46.6 (35–80) 124.8 (70–160) BS 50% identical
Zheng et al., 2001 mean 75.6 (70–90) mean 74.2 (70–80) 149.8 (140–170) REZ identical
Pollock et al., 2000 median 70 median 90 (70–120) 160 (140–190) REZ identical
* BS = brainstem; REZ = root entry zone.
† As additive value.
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Positive predictive factors for pain cessation rates 
taken from the published studies are complete pain relief 
after initial GKS, longer periods of pain relief, reduced 
topographic distribution of pain after a prior GKS, new 
trigeminal deficits, increasing isocenter distance between 
second and first GKS,67 and higher radiation dose.26 Neg-
ative predictors are no pain relief after a prior GKS24 and 
having undergone prior surgical procedure(s). No correla-
tion was found for age, sex, side, additive doses, or inter-
val between first and second GKS5,27,32 (Table 6).
Hypesthesia. The median rate for new hypesthesia af-
ter repeat GKS was 33% (range 11%–80%), much higher 
than that reported for first GKS (6%–54%). The main prob-
lem might not even be hypesthesia per se with retreatment 
but such complications as bothersome hypesthesia (up to 
16%),17,42 corneal numbness (up to 11%),1,42 dry eye (up to 
10.9%),32 taste changes (up to 8.7%),32 jaw weakness (up 
to 4%),32 and anesthesia dolorosa (which was difficult to 
quantify due to heterogeneity and lack of reporting).1
Positive predictive factors for new hypesthesia after 
second GKS, taken from the published studies, are good 
response to initial GKS (even at low doses), an additive 
dose greater than 115 Gy, isocenter placement (nearly 
identical location being reported by some studies as cre-
ating dysfunction), cumulative radiation dose to the lat-
eral pons (cutoff of 44 Gy), and cumulative DREZ dose 
(cutoff of 84.3 Gy).1 No correlation was found with regard 
to prior surgeries,26 pretreatment sensory impairment, 
first and/or second dose or additive doses,26 or the dis-
tance between isocenters (considered by other studies to 
be a positive predictor)42 (Table 7).
Summarizing current literature, hypesthesia onset is 
suggested to be a predictor for better long-term outcome 
but is not mandatory for maintaining pain relief. Also, in 
some studies, the occurrence of hypesthesia reached rates 
comparable to those with radiofrequency lesioning and/or 
balloon microcompression. Retreatment is more injuring 
than a first GKS.
Maintaining Pain Relief. As with all other techniques 
for TN, a second GKS is not a definitive therapy. There 
are 2 important issues when discussing maintenance of 
pain relief after second GKS: one is the necessity of hav-
ing long-term follow-up, as recurrences are more likely 
to occur 15–18 months after treatment; the second is that 
reported rates are fairly consistent or better compared 
with results of the first GKS (but there is shorter available 
follow-up compared with first treatment).
In the published studies, recurrences ranged between 
5.3% and 32% in the short term (median 24 months). 
Among studies reporting long-term follow-up, rates for 
maintaining pain relief at 5 years varied between 44.2%40 
and 72.7%.17 Additionally, in some studies, such as that by 
Verheul et al.,62 the curves for first and second GKS are 
almost identical for this outcome.
TABLE 5: Systematic review of the literature: results of second GKS
Authors & Year Initially Pain-Free >50%
Excellent Pain-Free 
(BNI Class I & II) Trigeminal Dysfunction New Facial Numbness
present study 89% 89% 33% 33.3%
Park et al., 2012 87% 32% 18% 18%
Aubuchon et al., 2011 81% 46% 57% 38%
Jones et al., 2011 100% NA NA NA
Kimball et al., 2010 91.30% 69.5% 47.8% 45.6%; 8.7% bothersome
Verheul et al., 2010 96% 70% NA 24%
Dvorak et al., 2009 61% 29% 29% 11%
Gellner et al., 2008 100.00% 76.2% 73.7% 73.7, 5.3% BNI III
Huang et al., 2008 60% NA NA 35%, 2 w/ BNI III, 1 w/ BNI IV
Wang et al., 2008 85.4% 53% NA 11.8%, 1 as somewhat bothersome
Huang et al., 2006 68% 43% 36% 36%, 10.7 somewhat bothersome, 4%  
 masseter weakness
Pollock et al., 2005 95% 74% 58%, 16% BNI III & IV 16% BNI III & IV, 11% corneal numbness
Sheehan et al., 2005 NA NA 36% 36%
Urgosik et al., 2005 89% 58% 33% 33% 
Zhang et al., 2005 65% 27% 10% (mainly dysesthesias), 
 3% severe
10% (mainly dysesthesias), 3% severe
Herman et al., 2004 88% 45% 11%, 5.5% BNI III & IV 11%, 5.5% BNI III & IV
Brisman, 2003 62% 22% 4% severe dysesthesias 8.8% BNI III, 4.4% BNI IV
Shetter et al., 2002 88% 53% 42% 42%
Hasegawa et al., 2002 85.2% 18.5% 12.7% 12.7%
Zheng et al., 2001 91.7% 75% 11% 11%
Pollock et al., 2000 90% 90% 80% 80%
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Positive predictive factors were partial recurrence 
after first GKS (partial better than complete), recurrence 
in a reduced topographic distribution, and additional sen-
sory dysfunction after a first treatment.32
Discussion
Medically unresponsive TN can be treated by 3 
methods: MVD, percutaneous techniques, and GKS. 
With the MVD technique, Barker et al.2 reported up to 
70% of patients remaining pain free at 10 years; for pa-
tients undergoing repeat MVD, 42% of cases had excel-
lent results at 10 years. Depending on the study, MVD 
recurrence rates on long-term basis range between 15% 
and 35%.2–4,7,8,10–12,18,28,30,52,55,56 For percutaneous tech-
niques, such as thermocoagulation, some trials reported 
a 57.7% pain-free response after a first procedure and up 
to 94% at 5-year follow-up after a second procedure.31 Fa-
cial numbness has been reported to occur in between 58% 
and 79% of patients.9,65 Gybels and Sweet19 reviewed 8 
published studies on thermocoagulation, involving more 
than 600 procedures; corneal numbness ranged from 1% 
to 35% and anesthesia dolorosa, from 0.6% to 25%.
Repeat radiosurgery emerged as an alternative to 
these 2 techniques, especially during the last 10 years. 
A number of clinical retrospective trials have shown 
that second GKS is a safe and effective procedure, with 
comparable or better initial pain cessation rates, despite 
a higher toxicity, which seems to be the tradeoff for main-
taining pain relief.1,5,14,17,22,24–27,32,38,42,63 Nevertheless, there 
is little consistent information to council patients on an 
individual basis, due to heterogeneity among papers re-
garding selection criteria and treatment parameters.
Among the 497 patients included in our study with 
initial pain cessation after the first GKS, 34.4% (157 of 
456 with ≥ 1-year follow-up) experienced at least 1 re-
currence; 112 of 157 required further treatment. Thirteen 
(1.8%) of the 737 patients were considered for a second 
GKS, a rate smaller than found in the published peer-
reviewed papers, which ranged in from 7%22 to 23.7%26 
(Table 3); this is explained by a different strategy of re-
peat GKS in our study.
Patient selection for retreatment is probably one of 
the most important issues. Why to retreat, when to retreat, 
and the patient profile are key conditions for therapeutic 
success. Our center uses strict selection criteria for sec-
ond GKS, related to an initial and prolonged pain cessa-
tion without medication, in the absence of other surgical 
alternatives. This is suggested by the median time for re-
treatment in our study, 72 months (range 12–125 months), 
compared with 17 months (range 12–125 months) in the 
literature reviewed. Also, previous studies discussing first 
GKS showed improved outcomes with no atypical fea-
tures,39,44 no prior surgical treatment,6,39,41 or no new tri-
geminal deficits.6,44 When reporting outcomes, we believe 
that these types of cases should be clearly separated.
Additionally, individual patient sensitivity to irradia-
tion might play a role. We might be selecting a subgroup 
of patients sensitive to radiation when treating only those 
responding well to the first GKS.
Another issue is related to doses. For GKS, a min-
imum dose of 70 Gy necessary for efficacy was estab-
lished in 1996 by a multicenter trial.34 As a maximum, 
in a baboon model Kondziolka et al.33 suggested that ne-
crosis occurred at 100 Gy. In this range, higher doses are 
related to better efficacy.53,64 Thus, our policy is to deliver 
90 Gy at 100% isodose, whenever the morphology of the 
cistern allows this dose prescription, while keeping doses 
to the brainstem low. This dose allows a low rate of toxic-
ity, provided that we use the retrogasserian target (7–8 
mm from the emergence).48 We kept the same dose and 
the same target placement at first and second GKS. 
The radiation target is important with respect to ini-
tial pain cessation and side effects. The heterogeneity re-
garding radiation target in published studies makes the 
“ideal” target difficult to establish.
Current literature is sparse, and there is a need for 
more follow-up and uniformity to establish state-of-the-
TABLE 6: Systematic review of the literature: predictors of initial 
pain cessation after second GKS
positive predictors
 initial complete pain relief after a prior GKS
 longer periods of pain relief after 1st GKS
 reduced distribution after 1st GKS
 new trigeminal deficits
 increasing distance btwn isocenters of 1st & 2nd radiation dose
negative predictors
 no pain relief after a prior GKS





 interval btwn GKS procedures
 dose rate at 2nd GKS
 radiation dose




 good response to initial GKS (even if 2nd GKS performed at low  
  doses)
 reduced distribution after 1st GKS
 an additive dose above 115 Gy
 nearly identical isocenter locations & mean dysfunction
 cumulative max radiation dose to lateral pons (cutoff 44 Gy)
no correlation
 prior surgeries
 pretreatment sensory impairment
 1st &/or 2nd dose, additive dose
 distance btwn isocenters
 which isocenter closer to brainstem
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art safety and efficacy for GKS retreatment. Pain control 
and recurrence rates seem comparable with first GKS in 
the literature we reviewed, with higher hypesthesia rates 
at second GKS in almost all studies. When investigating 
safety and efficacy, particular attention should be paid to 
individual patient characteristics at baseline, as well as to 
technical nuances, mainly target placement and radiation 
dose; additionally, the number of patients and duration of 
follow-up are important criteria.
Besides the relatively small sample size, our study 
raises the question of surgical alternatives after failed 
GKS for TN. The rates of initial pain cessation and recur-
rence seem comparable to or even better than those for 
the first GKS, according to different studies, but the toxic-
ity is much higher, both in our study and in the published 
data. However, because of the small number of patients in 
our study and limited available follow-up and heterogene-
ity of treatment philosophies in the reviewed studies, we 
do not have the answer to the 3 cardinal questions regard-
ing repeat radiosurgery in recurrent TN: which patients 
to retreat, which target is optimal, and which dose is opti-
mal. Reassessment of our database in 20 years’ time may 
offer sufficient numbers to answer these questions.
Conclusions
Our study is small compared with our general cohort 
due to very strict selection criteria for retreatment, mainly 
related to an initial and prolonged pain cessation without 
medication, in the absence of other surgical alternatives. 
Our study is differentiated from the other published stud-
ies by the use of the same technical parameters as the 
first GKS and much longer delay between first and second 
GKS, with a median of 72 months (range 12–125 months) 
at our institution compared with 17 months (range 3–146 
months) in the literature. Current available studies sug-
gest that second GKS is safe and effective, with an im-
portant increase in hypesthesia rates. Our attitude, due to 
this higher toxicity, is to propose MVD as a first intention 
therapy for recurrent TN after first GKS and to reserve 
second GKS for cases with no other surgical alternative.
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